Symbols / CRSP Stock $52.34 +3.21% CRISPR Therapeutics AG

Healthcare • Biotechnology • Switzerland • NGM
CRSP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Samarth Kulkarni Ph.D.
Exch · Country NGM · Switzerland
Market Cap 5.05B
Enterprise Value 3.25B
Income -581.60M
Sales 3.51M
FCF (ttm) -205.62M
Book/sh 20.04
Cash/sh 20.59
Employees —
Insider 10d —
IPO Oct 19, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -12.89
PEG —
P/S 1,437.98
P/B 2.61
P/C —
EV/EBITDA -5.93
EV/Sales 927.29
Quick Ratio 13.25
Current Ratio 13.32
Debt/Eq 10.76
LT Debt/Eq —
EPS (ttm) -6.47
EPS next Y -4.06
EPS Growth —
Revenue Growth -97.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-02-12
ROA -15.76%
ROE -30.18%
ROIC —
Gross Margin 0.00%
Oper. Margin -179.12%
Profit Margin 0.00%
Shs Outstand 96.43M
Shs Float 95.56M
Insider Own 5.90%
Instit Own 73.00%
Short Float 27.04%
Short Ratio 13.95
Short Interest 22.75M
52W High 78.48
vs 52W High -33.31%
52W Low 33.03
vs 52W Low 58.46%
Beta 1.79
Impl. Vol. 38.80%
Rel Volume 0.59
Avg Volume 1.90M
Volume 1.13M
Target (mean) $83.35
Tgt Median $80.00
Tgt Low $33.00
Tgt High $291.00
# Analysts 23
Recom Buy
Prev Close $50.71
Price $52.34
Change 3.21%
About

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$83.35
Mean price target
2. Current target
$52.34
Latest analyst target
3. DCF / Fair value
$-38.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$52.34
Low
$33.00
High
$291.00
Mean
$83.35

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-17 reit Piper Sandler Overweight → Overweight $110
2026-02-17 main Chardan Capital Buy → Buy $76
2026-02-13 main TD Cowen Hold → Hold $45
2026-02-13 main Evercore ISI Group Outperform → Outperform $74
2026-02-13 main Needham Buy → Buy $82
2026-01-30 main Citizens Market Outperform → Market Outperform $80
2025-12-23 reit Needham Buy → Buy $80
2025-12-23 reit Citizens Market Outperform → Market Outperform $86
2025-11-26 main Chardan Capital Buy → Buy $74
2025-11-12 main Citigroup Buy → Buy $77
2025-11-11 main RBC Capital Sector Perform → Sector Perform $50
2025-11-11 main Baird Neutral → Neutral $44
2025-11-10 main Needham Buy → Buy $80
2025-10-17 main B of A Securities Buy → Buy $93
2025-10-10 reit Needham Buy → Buy $81
2025-09-23 reit HC Wainwright & Co. Buy → Buy $80
2025-09-18 init JP Morgan — → Overweight $70
2025-08-07 main HC Wainwright & Co. Buy → Buy $80
2025-08-06 main Barclays Equal-Weight → Equal-Weight $56
2025-08-05 main Chardan Capital Buy → Buy $82
News
RSS: Latest CRSP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-23 KASINGER JAMES R. General Counsel — 3,182 $46.78 $148,854
2026-03-23 PRASAD RAJU Chief Financial Officer — 3,708 $46.78 $173,460
2026-03-23 KULKARNI SAMARTH Chief Executive Officer — 10,020 $46.78 $468,736
2026-03-20 KASINGER JAMES R. General Counsel — 6,250 — —
2026-03-20 PRASAD RAJU Chief Financial Officer — 6,250 — —
2026-03-20 KULKARNI SAMARTH Chief Executive Officer — 19,687 — —
2026-03-16 KASINGER JAMES R. General Counsel — 3,450 $48.26 $166,497
2026-03-16 PRASAD RAJU Chief Financial Officer — 750 $0.00 $0
2026-03-16 PRASAD RAJU Chief Financial Officer — 9,869 $48.26 $476,278
2026-03-16 PATEL NAIMISH M.D. Officer — 3,150 $48.26 $152,019
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
35.00
-90.54%
370.00
+84762.39%
0.44
Operating Revenue
0.00
-100.00%
35.00
-90.54%
370.00
+84762.39%
0.44
Cost Of Revenue
213.48
+76.92%
120.67
-7.36%
130.25
+18.14%
110.25
Reconciled Cost Of Revenue
213.48
+76.92%
120.67
-7.36%
130.25
+18.14%
110.25
Gross Profit
-213.48
-149.20%
-85.67
-135.73%
239.75
+318.32%
-109.81
Operating Expense
451.09
+18.43%
380.90
-17.61%
462.29
-17.94%
563.35
Research And Development
381.06
+22.83%
310.24
-19.90%
387.33
-16.10%
461.64
Selling General And Administration
73.54
+0.77%
72.98
-4.18%
76.16
-25.67%
102.46
General And Administrative Expense
73.54
+0.77%
72.98
-4.18%
76.16
-25.67%
102.46
Other Gand A
73.54
+0.77%
72.98
-4.18%
76.16
-25.67%
102.46
Other Operating Expenses
-3.51
-51.69%
-2.31
-91.87%
-1.21
-58.27%
-0.76
Total Expenses
664.57
+32.50%
501.57
-15.35%
592.54
-12.03%
673.60
Operating Income
-664.57
-42.44%
-466.57
-109.66%
-222.54
+66.94%
-673.16
Total Operating Income As Reported
-664.57
-42.44%
-466.57
-109.66%
-222.54
+66.94%
-673.16
EBITDA
-645.09
-44.22%
-447.31
-120.67%
-202.70
+68.77%
-648.99
Normalized EBITDA
-645.09
-44.22%
-447.31
-120.67%
-202.70
+68.77%
-648.99
Reconciled Depreciation
19.48
+1.14%
19.26
-2.91%
19.84
-17.93%
24.17
EBIT
-664.57
-42.44%
-466.57
-109.66%
-222.54
+66.94%
-673.16
Net Income
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Pretax Income
-577.97
-59.37%
-362.67
-140.62%
-150.72
+76.83%
-650.50
Other Income Expense
86.61
-16.65%
103.90
+44.68%
71.82
+216.91%
22.66
Other Non Operating Income Expenses
86.61
-16.65%
103.90
+44.68%
71.82
+216.91%
22.66
Tax Provision
3.63
+1.31%
3.59
+24.20%
2.89
+988.62%
-0.33
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+16900.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Net Income From Continuing Operation Net Minority Interest
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Net Income From Continuing And Discontinued Operation
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Net Income Continuous Operations
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Normalized Income
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Net Income Common Stockholders
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Diluted EPS
-6.47
-49.08%
-4.34
-123.71%
-1.94
+76.79%
-8.36
Basic EPS
-6.47
-49.08%
-4.34
-123.71%
-1.94
+76.79%
-8.36
Basic Average Shares
89.93
+6.60%
84.36
+6.49%
79.22
+1.90%
77.75
Diluted Average Shares
89.93
+6.60%
84.36
+6.49%
79.22
+1.90%
77.75
Diluted NI Availto Com Stockholders
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,265.24
+1.04%
2,242.03
+0.56%
2,229.57
-0.60%
2,243.06
Current Assets
1,985.67
+2.51%
1,937.13
+1.52%
1,908.08
+2.97%
1,853.03
Cash Cash Equivalents And Short Term Investments
1,975.83
+3.78%
1,903.83
+12.41%
1,693.69
-6.70%
1,815.32
Cash And Cash Equivalents
347.56
+16.53%
298.26
-23.42%
389.48
+83.82%
211.88
Other Short Term Investments
1,628.27
+1.41%
1,605.57
+23.11%
1,304.21
-18.66%
1,603.43
Receivables
0.00
-100.00%
25.00
-87.50%
200.00
0.00
Accounts Receivable
0.00
-100.00%
25.00
-87.50%
200.00
0.00
Prepaid Assets
—
—
—
—
Other Current Assets
9.84
+18.50%
8.31
-42.26%
14.39
-61.85%
37.71
Total Non Current Assets
279.57
-8.31%
304.90
-5.16%
321.49
-17.57%
390.03
Net PPE
247.57
-10.80%
277.55
-9.28%
305.94
-4.56%
320.56
Gross PPE
338.63
-3.20%
349.83
-2.66%
359.37
+1.41%
354.39
Accumulated Depreciation
-91.05
-25.99%
-72.27
-35.26%
-53.43
-57.94%
-33.83
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
12.71
+2.58%
12.39
+4.55%
11.85
+1.03%
11.73
Construction In Progress
3.96
-35.35%
6.12
-30.94%
8.86
+43.77%
6.16
Other Properties
175.30
-5.48%
185.47
-5.08%
195.40
+0.30%
194.82
Leases
146.67
+0.56%
145.85
+1.81%
143.26
+1.12%
141.68
Goodwill And Other Intangible Assets
—
0.00
-100.00%
0.02
-77.46%
0.07
Investments And Advances
—
0.00
-100.00%
1.97
-96.29%
53.13
Other Non Current Assets
32.00
+17.00%
27.35
+101.59%
13.57
-16.65%
16.27
Total Liabilities Net Minority Interest
343.43
+10.80%
309.95
-10.62%
346.77
-5.66%
367.58
Current Liabilities
149.12
+69.88%
87.78
-19.31%
108.79
-10.17%
121.11
Payables And Accrued Expenses
101.66
+80.78%
56.23
-32.99%
83.92
-20.26%
105.25
Payables
12.25
-19.19%
15.16
-60.71%
38.59
+39.99%
27.56
Accounts Payable
11.14
-24.28%
14.71
-61.44%
38.15
+39.08%
27.43
Current Accrued Expenses
89.41
+117.68%
41.07
-9.40%
45.34
-41.64%
77.68
Total Tax Payable
1.11
+146.78%
0.45
+2.97%
0.44
+224.44%
0.14
Current Debt And Capital Lease Obligation
18.58
+7.46%
17.29
+10.64%
15.62
-1.37%
15.84
Current Capital Lease Obligation
18.58
+7.46%
17.29
+10.64%
15.62
-1.37%
15.84
Current Deferred Liabilities
15.77
+310.17%
3.85
-6.33%
4.11
0.00
Current Deferred Revenue
15.77
+310.17%
3.85
-6.33%
4.11
0.00
Other Current Liabilities
13.11
+25.88%
10.42
+102.63%
5.14
+25605.00%
0.02
Total Non Current Liabilities Net Minority Interest
194.31
-12.54%
222.17
-6.64%
237.98
-3.45%
246.47
Long Term Debt And Capital Lease Obligation
188.17
-8.84%
206.41
-7.44%
223.01
-2.27%
228.18
Long Term Capital Lease Obligation
188.17
-8.84%
206.41
-7.44%
223.01
-2.27%
228.18
Non Current Deferred Liabilities
0.00
-100.00%
12.32
-12.05%
14.01
+13.71%
12.32
Non Current Deferred Revenue
0.00
-100.00%
12.32
-12.05%
14.01
+13.71%
12.32
Other Non Current Liabilities
6.14
+78.34%
3.44
+259.50%
0.96
-83.95%
5.97
Stockholders Equity
1,921.81
-0.53%
1,932.08
+2.62%
1,882.80
+0.39%
1,875.48
Common Stock Equity
1,921.81
-0.53%
1,932.08
+2.62%
1,882.80
+0.39%
1,875.48
Capital Stock
3.09
+14.42%
2.70
+8.05%
2.50
+2.29%
2.44
Common Stock
3.09
+14.42%
2.70
+8.05%
2.50
+2.29%
2.44
Share Issued
96.01
+11.75%
85.91
+7.10%
80.21
+1.93%
78.69
Ordinary Shares Number
95.89
+11.84%
85.74
+7.12%
80.04
+1.95%
78.51
Treasury Shares Number
0.12
-32.29%
0.17
+0.00%
0.17
-5.55%
0.18
Additional Paid In Capital
3,861.52
+17.24%
3,293.56
+14.43%
2,878.16
+5.24%
2,734.84
Retained Earnings
-1,947.55
-42.58%
-1,365.95
-36.64%
-999.70
-18.16%
-846.09
Gains Losses Not Affecting Retained Earnings
4.82
+162.01%
1.84
-3.82%
1.91
+112.23%
-15.65
Treasury Stock
0.06
-3.23%
0.06
+0.00%
0.06
-1.59%
0.06
Other Equity Adjustments
4.82
+162.01%
1.84
-3.82%
1.91
+112.23%
-15.65
Total Equity Gross Minority Interest
1,921.81
-0.53%
1,932.08
+2.62%
1,882.80
+0.39%
1,875.48
Total Capitalization
1,921.81
-0.53%
1,932.08
+2.62%
1,882.80
+0.39%
1,875.48
Working Capital
1,836.55
-0.69%
1,849.35
+2.78%
1,799.29
+3.89%
1,731.92
Invested Capital
1,921.81
-0.53%
1,932.08
+2.62%
1,882.80
+0.39%
1,875.48
Total Debt
206.75
-7.58%
223.69
-6.26%
238.63
-2.21%
244.02
Capital Lease Obligations
206.75
-7.58%
223.69
-6.26%
238.63
-2.21%
244.02
Net Tangible Assets
1,921.81
-0.53%
1,932.08
+2.62%
1,882.79
+0.39%
1,875.41
Tangible Book Value
1,921.81
-0.53%
1,932.08
+2.62%
1,882.79
+0.39%
1,875.41
Available For Sale Securities
—
—
1.97
-96.29%
53.13
Investmentin Financial Assets
—
0.00
-100.00%
1.97
-96.29%
53.13
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-345.01
-141.65%
-142.77
+45.17%
-260.38
+47.48%
-495.74
Cash Flow From Continuing Operating Activities
-345.01
-141.65%
-142.77
+45.17%
-260.38
+47.48%
-495.74
Net Income From Continuing Operations
-581.60
-58.80%
-366.25
-138.43%
-153.61
+76.37%
-650.17
Depreciation Amortization Depletion
19.48
+1.14%
19.26
-2.91%
19.84
-17.93%
24.17
Depreciation
19.40
+1.04%
19.20
—
—
Depreciation And Amortization
19.48
+1.14%
19.26
-2.91%
19.84
-17.93%
24.17
Other Non Cash Items
72.72
+288.32%
-38.62
-174.96%
-14.04
-212.63%
12.47
Stock Based Compensation
72.50
-16.25%
86.57
+6.84%
81.03
-17.27%
97.95
Change In Working Capital
71.88
-54.00%
156.27
+180.72%
-193.59
-1075.49%
19.84
Change In Receivables
25.00
-85.71%
175.00
+187.50%
-200.00
-65673.77%
0.30
Changes In Account Receivables
25.00
-85.71%
175.00
+187.50%
-200.00
-65673.77%
0.30
Change In Prepaid Assets
3.34
-36.86%
5.29
-77.24%
23.22
+1353.00%
1.60
Change In Payables And Accrued Expense
44.89
+264.55%
-27.28
-34.75%
-20.25
-492.08%
5.16
Change In Other Working Capital
-5.61
+11.78%
-6.36
-290.70%
3.33
-76.69%
14.30
Change In Other Current Liabilities
4.26
-55.76%
9.62
+8649.09%
0.11
+107.23%
-1.52
Investing Cash Flow
-31.80
+88.66%
-280.48
-174.87%
374.65
+244.84%
-258.65
Cash Flow From Continuing Investing Activities
-31.80
+88.66%
-280.48
-174.87%
374.65
+244.84%
-258.65
Net PPE Purchase And Sale
-0.91
+51.92%
-1.90
+79.93%
-9.47
+74.53%
-37.19
Purchase Of PPE
-0.91
+51.92%
-1.90
+79.93%
-9.47
+74.53%
-37.19
Capital Expenditure
-25.91
-1263.18%
-1.90
+84.12%
-11.97
+67.81%
-37.19
Net Investment Purchase And Sale
-5.89
+97.89%
-278.58
-172.06%
386.62
+274.57%
-221.47
Purchase Of Investment
-1,017.87
+31.52%
-1,486.38
-39.45%
-1,065.91
+24.82%
-1,417.80
Sale Of Investment
1,011.98
-16.21%
1,207.80
-16.85%
1,452.53
+21.42%
1,196.33
Gain Loss On Sale Of Business
—
—
—
—
Net Intangibles Purchase And Sale
-25.00
0.00
+100.00%
-2.50
0.00
Purchase Of Intangibles
-25.00
0.00
+100.00%
-2.50
0.00
Financing Cash Flow
426.03
+28.33%
331.98
+429.78%
62.66
+62.38%
38.59
Cash Flow From Continuing Financing Activities
426.03
+28.33%
331.98
+429.78%
62.66
+62.38%
38.59
Net Common Stock Issuance
398.09
+32.39%
300.69
+818.97%
32.72
+3273.30%
0.97
Proceeds From Stock Option Exercised
27.94
-10.72%
31.29
+4.50%
29.94
-20.41%
37.62
Changes In Cash
49.21
+153.91%
-91.27
-151.58%
176.94
+124.72%
-715.80
Effect Of Exchange Rate Changes
0.10
+552.38%
-0.02
-128.77%
0.07
+191.25%
-0.08
Beginning Cash Position
309.78
-22.76%
401.07
+79.00%
224.06
-76.16%
939.94
End Cash Position
359.08
+15.92%
309.78
-22.76%
401.07
+79.00%
224.06
Free Cash Flow
-370.93
-156.39%
-144.68
+46.88%
-272.35
+48.90%
-532.93
Amortization Of Securities
—
—
—
—
Common Stock Issuance
398.09
+32.39%
300.69
+818.97%
32.72
+3273.30%
0.97
Earnings Losses From Equity Investments
—
—
—
—
Issuance Of Capital Stock
398.09
+32.39%
300.69
+818.97%
32.72
+3273.30%
0.97
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category